Eli Lilly’s revenue is tracking upward, its share price has climbed and its market cap has skyrocketed to the highest in the biopharma industry.
It's little wonder, then, that its executives, led by CEO David Ricks, are raking in the rewards. In 2023, Ricks received a 24% boost in pay from $21.4 million to $26.6 million, according to the company’s proxy filing.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,